Navigation Links
Study Shows Coronado Biosciences' Bcl-2 Inhibitor, Apogossypol, is More Efficacious, Less Toxic than Gossypol in Animal Models

Published Paper Provides Rationale for Continued Development of CNDO103 as

Cancer Treatment

SAN DIEGO, Jan. 28 /PRNewswire/ -- Coronado Biosciences Inc. today announced the publication of data demonstrating that the Bcl-2 inhibitor, Apogossypol, effectively killed a variety of cancer cells in vitro while demonstrating less toxicity than Gossypol in vivo in mice.

Published online in Blood (Jan. 17, DOI 10.1182/blood-2007-09-113647) by the Burnham Institute's president and CEO, John Reed, M.D., Ph.D., and collaborators, the paper summarized study findings demonstrating that mice treated with Apogossypol experienced less hepatotoxicity and gastrointestinal toxicity than those treated with Gossypol. The results support Coronado Biosciences' continued development of its lead candidate, CNDO103, as a cancer treatment.

"Apogossypol was rationally designed to eliminate the toxicities seen with Gossypol," said Reed. "This study provides strong evidence that Apogossypol is better tolerated by the animals without a compromise in potency in vitro. We hope these preclinical results translate to humans. If they do, Apogossypol can play a role in the treatment of many types of cancers."

Maurizio Pellecchia, Ph.D., a professor at the Burnham Institute of Medical Research, developed Apogossypol using NMR guided rational drug design. "Based on our molecular modeling, we predicted that Apogossypol would be equally potent in killing cancer cells but safer than the parent compound Gossypol," said Pellecchia. "It is gratifying that the exhaustive set of experiments reported in the paper support our predictions."

RJ Tesi, M.D., president and CEO of Coronado Biosciences, added: "The data reinforce our decision to push rapidly to the clinic with Apogossypol. We plan to perform IND-enabling preclinical studies for Apogossypol, CNDO103, in the first half of the year. If the toxicity profile in animals approximates what was shown in this work, we plan to file an IND in late 2008."

About CNDO103

CNDO103 is Apogossypol, a rationally designed derivative of Gossypol. Apogossypol targets the Bcl-2 family pro-survival proteins class -- inhibiting five of the six members of the Bcl-2 family. In preclinical studies, oral Apogossypol appears to have improved physiologic and pharmaceutical properties compared to other drugs in the same class. Apogossypol shows activity against both hematologic and epithelial tumors.

The Bcl-2 family of proteins control naturally occurring, programmed cell death called apoptosis. In cancer, increased levels of the Bcl-2 pro-survival proteins lead to abnormal apoptosis, uncontrolled cell growth and the development of resistance to standard therapies. The inhibition of Bcl-2 pro-survival proteins may normalize apoptosis, cause tumor shrinkage and make resistant tumors sensitive to standard treatments.

Burnham Institute for Medical Research

Burnham Institute for Medical Research conducts world-class collaborative research dedicated to finding cures for human disease, improving quality of life, and thus creating a legacy for its employees, donors, and community. The Institute is headquartered in La Jolla, Calif., where it was established as a nonprofit, public benefit corporation in 1976 and is now home to four centers: a National Cancer Institute-designated Cancer Center; the Del E. Webb Center for Neurosciences, Aging and Stem Cell Research; the Infectious and Inflammatory Disease Center and the Sanford Children's Health Research Center. In 2006, Burnham established a center for bionanotechnology research at the University of California, Santa Barbara. Burnham is currently establishing a campus at Lake Nona in Orlando, Florida that will focus on diabetes and obesity research and will expand the Institute's drug discovery capabilities. Today, Burnham employs more than 820 people and ranks consistently among the world's top 25 organizations for its research impact and among the top four research institutes nationally for NIH grant funding. For additional information about Burnham and to learn about ways to support its research, visit

About Coronado Biosciences Inc.

Coronado Biosciences Inc. is a clinical stage biopharmaceutical company that is focused on changing cancer care by improving current therapies. The company's pipeline consists of both clinical and preclinical compounds that will offer unique options to physicians and patients. By mitigating scientific, development and financial risk, the company increases the likelihood of developing marketable drugs with the potential for broad indications. For more information, call (858) 731-8517 or visit

Contact: Tracey Milani or David Schull

Russo Partners, LLC


SOURCE Coronado Biosciences Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Kline Study: Better Brushing Habits Boost European Oral Care Sales
4. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
5. NASA study will help stop stowaways to Mars
6. New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome
7. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
8. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
9. Study Supports Use of GlycoMark Blood Test to Evaluate Therapy in Children with Diabetes
10. Quigley Corporation Releases Update on Quigley Pharmas Phase IIb Clinical Study of QR-333 in Diabetic Peripheral Neuropathy
11. Biodel Inc. Announces VIAject(TM) Phase II Meal Study Data at the 2007 European Association for the Study of Diabetes Meeting
Post Your Comments:
(Date:10/12/2017)... ... October 12, 2017 , ... ... the pharmaceutical and biotechnology industries to improve patient outcomes and quality of life, ... in analytical testing are being attributed to new regulatory requirements for all new ...
(Date:10/11/2017)... ... October 11, 2017 , ... At its national board ... Suneel I. Sheikh, the co-founder, CEO and chief research scientist of Minnesota-based Advanced ... for membership in ARCS Alumni Hall of Fame . ASTER Labs is ...
(Date:10/11/2017)... ... ... wash is a basic first aid supply for any work environment, but most personal eye ... first if a dangerous substance enters both eyes? It’s one less decision, and likely quicker ... eye piece. , “Whether its dirt and debris, or an acid or alkali, getting anything ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... today it will be hosting a Webinar titled, “Pathology is going digital. Is ... , on digital pathology adoption best practices and how Proscia improves lab economics ...
Breaking Biology Technology:
(Date:5/16/2017)... May 16, 2017  Veratad Technologies, LLC ( ... age and identity verification solutions, announced today they will ... 2017, May 15 thru May 17, 2017, in ... International Trade Center. Identity impacts the ... in today,s quickly evolving digital world, defining identity is ...
(Date:5/6/2017)... -- RAM Group , Singaporean based technology ... biometric authentication based on a novel  quantum-state ... perform biometric authentication. These new sensors are based on a ... Group and its partners. This sensor will have widespread ... security. Ram Group is a next generation sensor ...
(Date:4/19/2017)... New York , April 19, 2017 ... competitive, as its vendor landscape is marked by the ... the market is however held by five major players ... Safran. Together these companies accounted for nearly 61% of ... of the leading companies in the global military biometrics ...
Breaking Biology News(10 mins):